Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 194

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 194
---
                                                                                                                                                                                                           |

- 135 -

| company for all or a portion of the award and any amounts paid under the award in order to comply with the clawback policy or applicable laws. |

| • |     | No tax gross-ups. The Amended and Restated Plan does not provide for any tax gross-ups. |

Our directors and named executive officers have an interest in this proposal as they are eligible to receive equity awards under the Amended and Restated Plan. Summary of the Amended and Restated Plan The following is a summary of the principal features of the Amended and Restated Plan and its operation. It is qualified in its entirety by reference to the Amended and Restated Plan set forth in this proxy statement as Appendix H. The Amended and Restated Plan provides for the grant of the following types of incentive awards: (i) stock options, (ii) restricted stock, (iii) restricted stock units, (iv) stock appreciation rights, and (v) performance units and performance shares. Each of these is referred to individually as an “Award.” Those eligible for Awards under the Amended and Restated Plan include members of the board of directors and employees and consultants who provide services to us or any parent or subsidiary of ours. As of January 30, 2025, we had approximately 39 employees and 9 outside directors who were eligible to participate in this Amended and Restated Plan. Consultants as a class are also eligible to participate in this Amended and Restated Plan, though our consultants typically have not receive equity awards and only two out of 17 of our current consultants have been granted equity awards as of January 31, 2025, with the Administrator potentially considering awards to an additional two consultants. As stated, the Amended and Restated Plan allows us to grant Awards to consultants, and in certain circumstances, we have granted Awards to individual consultants of the Company performing a critical function. Number of Shares of Common Stock Available Under the Amended and Restated Plan. On January 20, 2025, upon recommendation of the Compensation Committee, Aadi’s board of directors approved the addition of an incremental 6,300,000 shares to the Amended and Restated Plan subject to stockholder approval. As of January 30, 2025, a total of (i) 2,070,784 shares were authorized for issuance under our 2021 Plan, plus (ii) any shares subject to stock options or similar awards granted under the Aerpio Pharmaceuticals, Inc.